AMD\NYU.210
[*] indicates that a confidential portion of the text of this agreement has been
omitted and filed separately with the Securities and Exchange Commission
THIRD AMENDMENT TO LICENSE AGREEMENT
This Third Amendment to License Agreement (hereinafter the "Amendment "),
is made and effective on June 12, 1997, by and between XOMA CORPORATION, a
corporation organized and existing under the laws of the State of Delaware and
having a place of business at 0000 Xxxxxxx Xxxxxx, Xxxxxxxx, Xxxxxxxxxx 00000
(hereinafter "CORPORATION"), and NEW YORK UNIVERSITY, a corporation organized
and existing under the laws of the State of New York and having a place of
business at 00 Xxxxxxxxxx Xxxxxx Xxxxx, Xxx Xxxx, Xxx Xxxx, 00000 (hereinafter
"NYU").
WHEREAS, CORPORATION and NYU have entered into a certain agreement (the
"Agreement") made and effective as of August 6, 1990 (the "Effective Date"), as
amended and restated on September 1, 1993, pursuant to which, inter alia,
CORPORATION undertook to sponsor the NYU Research Project (as such term is
defined in the Agreement) and NYU granted to CORPORATION the License (as such
term is defined in the Agreement); and
WHEREAS, CORPORATION and NYU wish to amend and extend the Agreement under
certain terms as specified herein;
NOW, THEREFORE, in consideration of the premises and the covenants,
conditions and promises set forth below, the parties hereto hereby agree as
follows:
1. Except as expressly provided for herein, all terms and conditions of the
Agreement shall remain in full force and effect.
2. Terms which are defined in the Agreement shall have the same meanings when
used in this Amendment, unless a different definition is given herein.
3. The second line of Subsection 1.d. of the Agreement shall be, and hereby
is, amended to read as follows:
BPI that NYU had in its possession on the Effective Date
4. The first line of Subsection 1.e.i) of the Agreement shall be, and hereby
is, amended to read as follows:
any product for therapeutic or prophylactic use.
5. The first line of Subsection 1.r.i) shall be, and hereby is, amended to
read as follows:
any product for therapeutic or prophylactic use.
6. Section 1.v. of the Agreement shall be, and hereby is, amended in its
entirety so that, as amended, said Section 1.v. shall read as follows:
v. "Research Period" shall mean the eight (8) year period commencing upon
the Effective Date and any extension thereof as to which NYU and
CORPORATION shall mutually agree in writing.
7. Section 4.a. of the Agreement shall be, and hereby is, amended in its
entirety so that, as amended, said Section 4.a. shall read as follows:
a. As compensation to NYU for work performed on the NYU Research Project
during the Research Period, CORPORATION shall pay NYU (i) the sum of [*]
payable in accordance with the Schedule annexed to the Agreement as
Appendix V, which forms an integral part thereof; NYU acknowledges that as
of June 12, 1997, CORPORATION has paid NYU this amount in full; and (ii)
the sum of [*] in two equal, consecutive, semi-annual installments, the
first of which shall be due on or before August 31, 1997.
8. The ninth line of Subsection 9.a.(l) of the Agreement shall be, and hereby
is, amended by adding a comma and the following language after the word
earlier and before the semicolon:
[*]
9. The ninth line of Subsection 9.a.(2) of the Agreement shall be, and hereby
is, amended by adding the following language after the word and:
[*]
10. The third line of Subsection 9.a.(3) of the Agreement shall be, and hereby
is, amended by adding the following language after the word Entity):
[*]
2
[*]
11. The third line of Subsection 9.a.(4) of the Agreement shall be, and hereby
is, amended by adding the following language after the word Entity):
[*]
12. The sixth line of Subsection 9.a.(5) of the Agreement shall be, and hereby
is, amended by adding the following language after the word Entity):
[*]
13. The second line of Subsection 9.e. of the Agreement shall be, and hereby
is, amended by the addition of the following language after the word
"Product" and the deletion of the comma after such word:
for any human diagnostic, prophylactic or therapeutic use
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as
follows:
NEW YORK UNIVERSITY XOMA CORPORATION
By: /s/ Xxxxx X. Xxxxxxxx By: /s/Xxxxxxxxxxx X. Xxxxxxxx
Xxxxx X. Xxxxxxxx Xxxxxxxxxxx X. Xxxxxxxx
Associate Xxxx and Vice Vice President, General
President for Industrial Counsel and Secretary
Liaison
Date: 6/20/97 Date: 6/17/97
